Prophylaxis of hepatitis B virus recurrence after liver transplantation

Journal of Gastrointestinal and Liver Diseases

Volumn 18, Issue 2, 2009, Pages 139-141

  Testino, Gianni ^a   Borro, Paolo ^a   Sumberaz, Alessandro ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR DIPIVOXIL; HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; VIRUS DNA; ANTIVIRUS AGENT; IMMUNOGLOBULIN;

ANTIBODY TITER; COMBINATION CHEMOTHERAPY; DRUG COST; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EDITORIAL; GENE MUTATION; GRAFT SURVIVAL; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; LIVER TRANSPLANTATION; LOW DRUG DOSE; MAINTENANCE THERAPY; MONOTHERAPY; RECURRENT DISEASE; RISK REDUCTION; SURVIVAL RATE; UNSPECIFIED SIDE EFFECT; VIRUS LOAD; VIRUS REPLICATION; BLOOD; COST BENEFIT ANALYSIS; DRUG COMBINATION; ECONOMICS; FEMALE; GENETICS; HEALTH CARE COST; IMMUNOLOGY; MALE; MIDDLE AGED; NOTE; PATIENT SELECTION;

ANTIVIRAL AGENTS; COST-BENEFIT ANALYSIS; DNA, VIRAL; DRUG COSTS; DRUG THERAPY, COMBINATION; FEMALE; HEALTH CARE COSTS; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; LAMIVUDINE; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PATIENT SELECTION; RECURRENCE; VIRAL LOAD;

EID: 70149084229     PISSN: 18418724     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (35)

1. Kotlyar DS, Campbell MS, Reddy KR. Recurrence of diseases following orthotopic liver transplantation. Am J Gastroenterol 2006; 101: 1370-1378. (Pubitemid 43830007)
2. Iacob S, Gheorghe L, Hrehoret D, Becheanu G, Herlea V, Popescu I. Pegylated Interferon alpha-2a and ribavirin combination therapy in HCV liver transplantation recipients. Experience of 7 cases. J Gastrointestin Liver 2008; 17: 165-172. (Pubitemid 351930762)
3. Testino G, Sumberaz A, Ravetti G, Gentile R, Ansaldi F, Icardi G. Pegylated interferon (PEG-IFN) alfa-2b and ribavirin for recurrent hepatitis C (genotype 1) after liver transplantation: relationship with steatosis. Dig Liver Dis 2006; 38: 864-865. (Pubitemid 44430935)
4. Iacob S, Hrehoret D, Matei E, et al. Costs and effi cacy of "on demand" low-dose immunoprophylaxis in HBV transplanted patients: experience in the Romanian program of liver transplantation. J Gastrointestin Liver Dis 2008; 17: 383-388.
5. Han SH, Martin P, Edelstein M, et al. Conversion from intravenous to intramuscular hepatitis B immune globulin in combination with lamivudine is safe and cost-effective in patients receiving ling-term prophylaxis to prevent hepatitis B recurrence after liver transplantation. Liver Transpl 2003; 9: 182-187. (Pubitemid 36204568)
6. Roche B, Samuel D. Liver transplantation for hepatitis B virus-related liver disease: indications, prevention of recurrence and results. J Hepatol 2003; 39: S181-S189. (Pubitemid 37222670)
7. Steinmuller T, Seehofer D, Rayes N, et al. Increasing applicability of liver transplantation for patients with hepatitis B-related disease. Hepatology 2002; 35: 1528-1535. (Pubitemid 34966909)
8. Villamil FG. Hepatitis B: progress in the last 15 years. Liver Transpl 2002; 8 (10 Suppl 1): S59-S66.
9. Conjeevaram HS, Lok AS. Management of chronic hepatitis B. J Hepatol 2003; 38 (Suppl 1): S90-S103.
10. Marzano A, Gaia S, Ghisetti V, et al. Viral load at the time of liver transplantation and risk of hepatitis B virus recurrence. Liver Transpl 2005; 11: 402-409. (Pubitemid 40533208)
11. Franchello A, Ghisetti V, Marzano A, Romagnoli R, Salizzoni M. Transplantation of hepatitis B surface antigen-positive livers into hepatitis B virus-positive recipients and the role of hepatitis delta coinfection. Liver Transpl 2005; 11: 922-928. (Pubitemid 41122449)
12. Berenguer M. Host and donor risk factors before and after liver transplantation that impact HCV recurrence. Liver Transpl 2003; 9: S44-S47. (Pubitemid 37408002)
13. Rapti I, Dimou E, Mitsoula P, Hadziyannis SJ. Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAgnegative chronic hepatitis B. Hepatology 2007; 45: 307-313. (Pubitemid 46374587)
14. Lo CM, Liu CL, Lau GK, Chan SC, Ng IO, Fan ST. Liver transplantation for chronic hepatitis B with lamivudine-resistant YMDD mutant using add-on adefovir dipivoxil plus lamivudine. Liver Transpl 2005; 11: 807-813.
15. Marzano A, Lampertico P, Mazzaferro V, et al. Prophylaxis of hepatitis B virus recurrence after liver transplantation in carriers of lamivudine-resistant mutants. Liver Transpl 2005; 11: 532-538. (Pubitemid 40704065)
16. Marzano A, Angelucci E, Andreone P, et al. Prophylaxis and treatment of hepatitis B in immunocompromised patients. Dig Liver Dis 2007; 39: 397-408.
17. Carosi G, Rizzetto M. Treatment of chronic hepatitis B: recommendations from an Italian workshop. Dig Liver Dis 2008; 40: 603-617.
18. Filipponi R, Salizzoni M. Effi cacy, safety and pharmacokinetic profi le of pasteurized intramuscular anti-hepatitis B immunoglobulin for the prophylaxis of hepatitis B virus recurrence after liver transplantation. Dig Liver Dis 2007; 39: A34.
19. Marzano A, Andreone P, Volpes R et al. Pharmacokinetics, effi cacy and safety of intramuscular and intravenous of hepatitis B immunoglobulins combined with nucleoside analogues in prophylaxis of hepatitis B after liver transplantation. Dig Liver Dis 2008; 40: A16.
20. Hooman N, Rifai K, Hadem J, et al. Antibody to hepatitis B surface antigen through levels and half-lives do not differ after intravenous and intramuscular hepatitis B immunoglobulin administration after liver transplantation. Liver Transpl 2008; 14: 435-442.
21. Marzano A. Liver transplantation for hepatitis B virus: an update on prophylaxis. Minerva Gastroenterol Dietol 2005; 54 (Suppl 1): 5-10.
22. Fagiuali S, Mirante VG, Pompili M, et al; Monotematica AISF 2000-OLT Study Group. Liver transplantation: the Italian experience. Dig Liver Dis 2002; 34: 640-648.
23. Angeli P, Scaglione F. Nephrotoxicity of intravenous immunoglobulins in the setting of liver transplantation for HBV-related cirrhosis: an underevalued topic? Minerva Gastroenterol Dietol 2008; 54: 259-275.
24. Orbach H, Tishler M, Shoenfeld Y. Intravenous immunoglobulin and the kidney- a two-edged sword. Semin Arthritis Rheum 2004; 34: 593-601. (Pubitemid 39643121)
25. Roche B, Samuel D. Evolving strategies to prevent HBV recurrence. Liver Transpl 2004; 10 (10 Suppl 2): S74-S85. (Pubitemid 39406104)
26. Burbach GJ, Bienzle U, Neuhaus R, et al. Intravenous or intramuscular anti-HBs immunoglobulin for the prevention of hepatitis B reinfection after orthotopic liver transplantation. Transplantation 1997; 63: 478-480. (Pubitemid 27086047)
27. Partovi N, Guy MW, Ensom MH, Noble MA, Yoshida EM. A study of the pharmacokinetic profi le of low-dose hepatitis B immune globulin in long-term liver transplant recipients for chronic hepatitis B infection. Am J Transplant 2001; 1: 51-54. (Pubitemid 33681681)
28. Samuel D, Roque-Alfonso AM. New sensitive tools for hepatitis B virus (HBV) detection in liver transplantation: what will be their impact on the prophylaxis of HBV infection? Liver Transpl 2007; 13: 1084-1087.
29. Caccamo L, Agnelli F, Reggiani P, et al. Role of lamivudine in the posttransplant prophylaxis of chronic hepatitis B virus and hepatitis delta virus coinfection. Transplantation 2007; 83: 1341-1344. (Pubitemid 46800310)
30. Caccamo L. Early use of the intramuscular route: the advantages. Minerva Gastroenterol Dietol 2008; 54 (Suppl 1): 11-17.
31. Di Paolo D, Tisone G, Piccolo P, Lenci I, Zazza S, Angelico M. Low-dose hepatitis B immunoglobulin given "on demand" in combination with lamivudine: a highly cost-effective approach to prevent recurrent hepatitis B virus infection in the long-term follow-up after liver transplantation. Transplantation 2004; 77: 1203-1208.
32. Jiao ZY, Jiao Z. Prophylaxis of recurrent hepatitis B in Chinese patients after liver transplantation using lamivudine combined with hepatitis B immune globulin according to the titer of antibody to hepatitis B surface antigen. Transplant Proc 2007; 39: 1533-1536. (Pubitemid 46907920)
33. Yilmaz N, Shiffman ML, Todd Stravitz R, et al. Prophylaxsis against recurrence of hepatitis B virus after liver transplantation : a retrospective analysis spanning 20 years. Liver Int 2008; 28: 72-78.
34. Gane EJ, Angus PW, Strasser S, et al; Australasian Liver Transplant Study Group. Lamivudine plus low-dose hepatitis B immunoglobulin to prevent recurrent hepatitis B following liver transplantation. Gastroenterology 2007; 132: 931-937.
35. Limquiaco JL, Wong J, Wong VW, et al. Lamivudine monoprophylaxis and adefovir salvage for liver transplantation in chronic hepatitis B: a seven-year follow-up study. J Med Virol 2009; 81: 224-229.